ctDNA Tumor Fraction as a Prognostic Biomarker in #TALAPRO3: Talazoparib + Enzalutamide in HRR-mutated #mCSPC. Presented by @AzadOncology @PeterMacCC. #ESMO26 written coverage by @

UroToday.com· @urotoday · X·2026-10-24 05:30· 1 day agoScore45

Body · original

ctDNA Tumor Fraction as a Prognostic Biomarker in #TALAPRO3: Talazoparib + Enzalutamide in HRR-mutated #mCSPC. Presented by @AzadOncology @PeterMacCC. #ESMO26 written coverage by @zklaassen_md > https://bit.ly/4zTljYw #ProstateCancer #PrecisionOncology @myESMO

257 views · 3 likes · 3 reposts · 0 replies

Conference abstracts

2219RONCT04746300matched by Rapid oral: Genitourinary tumours, prostate, penile and testis

Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metasta

https://esmocongress.esmo.org

Source: UroToday.com · x.com